A 52 wk [week] randomized, doubleblind, single dummy, parallel group multicenter phase 3 study comparing the long term safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered-dose inhaler] 4x160/4.5mcg bid to SymbicortpMDI 2x160/4.5mcg Bid and budesonide HFA [hydro fluoro alkane] pMDI 4x160mcg bid in adult and adolescent subjects with asthma.

Trial Profile

A 52 wk [week] randomized, doubleblind, single dummy, parallel group multicenter phase 3 study comparing the long term safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered-dose inhaler] 4x160/4.5mcg bid to SymbicortpMDI 2x160/4.5mcg Bid and budesonide HFA [hydro fluoro alkane] pMDI 4x160mcg bid in adult and adolescent subjects with asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Budesonide; Budesonide/formoterol
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Mar 2009 Efficacy results reported at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top